ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2404

Clinical features of Elderly-onset Systemic Lupus Erythematosus

Jessica Dai1, Erin Carter2, Mala Masson3, Amit Saxena4, H Michael Belmont5, Peter Izmirly6 and Jill Buyon4, 1New York University Grossman School of Medicine, Tenafly, NJ, 2New York University Grossman School of Medicine, New York, NY, 3NYU Langone Medical Center- Division of Rheumatology, New York, NY, 4NYU Grossman School of Medicine, New York, NY, 5NYU School of Medicine, New York, NY, 6New York University Grossman School of Medicine, New York, NY

Meeting: ACR Convergence 2025

Keywords: Aging, classification criteria, Disease Activity, geriatrics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic chronic disease characterized by a wide range of clinical and serological manifestations. It most commonly affects young women, with incidence and disease activity typically declining with age. As a result, data regarding the diagnoses of SLE in individuals ≥60 years of age (elderly onset SLE) is scarce. To better characterize elderly-onset SLE, a multi-racial cohort of SLE patients was analyzed.

Methods: This analysis leverages a cohort of 1141 SLE patients who met SLE criteria by at least one method: American College of Rheumatology (ACR), Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), and/or 2019 ACR/European League Against Rheumatism (EULAR) classification criteria. Lupus manifestations at the time of diagnosis were compared between elderly-onset SLE patients and those diagnosed at < 60 years old. An analysis of SLE presentation and diagnosis was conducted for elderly-onset SLE patients, including whether SLE diagnoses occurred during hospitalization, following referral to a rheumatologist, or through ongoing rheumatology clinic follow-up.

Results: Of 1141 patients with SLE, 90% were female and 10% were male. The racial and ethnic composition was as follows: 30% Black, 26% Hispanic, 22% White, 16% Asian, and 5% of unknown race/ethnicity. Within this cohort, 43 individuals were diagnosed at age ≥60 years (3.8%), while 1,098 were diagnosed at age < 60 years (96.2%). Additionally, there was a trend toward men being more likely to be diagnosed at age ≥60 years compared to those under 60 (19% vs. 10%, p=0.06). Among the 43 elderly-onset SLE patients, 9 were diagnosed between the ages of 65-69 and 10 were diagnosed at age ≥ 70, with the oldest being 82 years old. In this group, 28% had lupus nephritis (LN), with 6 patients later confirmed by a kidney biopsy. Compared to the remainder of the cohort, elderly-onset SLE patients exhibited significantly lower frequencies of malar rash at presentation (12% vs. 41%, p=0.0001), arthritis (33% vs. 69%, p ≤0.0001), and lupus nephritis (28% vs. 50%, p=0.004. (Table 1.) A majority of patients were diagnosed with SLE during hospitalization (47%), with 80% presenting with lupus-related complaints, and 20% presenting for SLE-unrelated issues (Table 2). The remaining diagnoses were made following referrals from a primary care physician or general rheumatologist (44%), with 11% of these referrals seeking evaluation for conditions other than lupus (Table 3).

Conclusion: This analysis identifies a distinct clinical profile in elderly-onset systemic lupus erythematosus (SLE). Despite immunosenescence, nearly 30% developed lupus nephritis (LN), with almost half diagnosed during hospitalization following severe symptom onset. Only one of 12 LN cases was referred by a rheumatologist for proteinuria; in most, renal involvement was recognized only after diagnosis of other SLE manifestations. These findings suggest new onset SLE and LN may be underrecognized in the elderly, leading to delayed diagnosis and increased disease severity.

Supporting image 1Table 1. Lupus clinical criteria profile for elderly-onset patients and patients diagnosed < 60 years of age

Supporting image 2Table 2. Hospitalization chief complaints in elderly-onset lupus patients

Supporting image 3Table 3. Reasons for rheumatology referrals in elderly-onset lupus patients


Disclosures: J. Dai: None; E. Carter: None; M. Masson: None; A. Saxena: AbbVie/Abbott, 1, Amgen, 1, AstraZeneca, 1, Aurinia, 1, 6, Bristol-Myers Squibb(BMS), 1, GlaxoSmithKlein(GSK), 5, Synthekine, 1, 2, UCB, 1, 6; H. Belmont: None; P. Izmirly: Hansoh Bio, 2; J. Buyon: Artiva Biotherapeutics, 2, Biogen, 2, Bristol-Myers Squibb(BMS), 2, Celgene, 2, CLIMB Bio Operating, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Related Sciences, 2, UCB, 2.

To cite this abstract in AMA style:

Dai J, Carter E, Masson M, Saxena A, Belmont H, Izmirly P, Buyon J. Clinical features of Elderly-onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/clinical-features-of-elderly-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-of-elderly-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology